| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Transplantation | 41 | 2025 | 1105 | 9.310 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 43 | 2024 | 393 | 7.600 |
Why?
|
| Carcinoma, Hepatocellular | 26 | 2026 | 967 | 5.280 |
Why?
|
| Liver Neoplasms | 27 | 2026 | 1350 | 4.770 |
Why?
|
| End Stage Liver Disease | 22 | 2025 | 184 | 4.010 |
Why?
|
| Hepatitis C, Chronic | 18 | 2022 | 363 | 3.880 |
Why?
|
| Hepatitis C | 15 | 2026 | 382 | 3.610 |
Why?
|
| Liver Diseases, Alcoholic | 10 | 2023 | 59 | 3.340 |
Why?
|
| Liver Cirrhosis | 36 | 2026 | 875 | 3.330 |
Why?
|
| Antiviral Agents | 17 | 2022 | 776 | 2.460 |
Why?
|
| Hepacivirus | 12 | 2023 | 266 | 2.270 |
Why?
|
| Fatty Liver | 11 | 2026 | 205 | 2.190 |
Why?
|
| Waiting Lists | 13 | 2024 | 236 | 2.090 |
Why?
|
| Tissue and Organ Procurement | 7 | 2025 | 248 | 1.970 |
Why?
|
| Coronavirus Infections | 5 | 2020 | 363 | 1.940 |
Why?
|
| Pneumonia, Viral | 5 | 2020 | 376 | 1.930 |
Why?
|
| Tissue Donors | 10 | 2025 | 506 | 1.870 |
Why?
|
| Nutrition Surveys | 23 | 2025 | 305 | 1.790 |
Why?
|
| Hepatitis, Alcoholic | 6 | 2025 | 25 | 1.610 |
Why?
|
| United States | 63 | 2026 | 11425 | 1.580 |
Why?
|
| Gastrointestinal Diseases | 3 | 2021 | 337 | 1.540 |
Why?
|
| Betacoronavirus | 5 | 2020 | 285 | 1.410 |
Why?
|
| Humans | 148 | 2026 | 127501 | 1.280 |
Why?
|
| Pandemics | 15 | 2024 | 1141 | 1.160 |
Why?
|
| Risk Factors | 38 | 2025 | 10636 | 1.150 |
Why?
|
| Hospitalization | 13 | 2024 | 1878 | 1.140 |
Why?
|
| Retrospective Studies | 46 | 2025 | 17080 | 1.100 |
Why?
|
| Graft Survival | 9 | 2025 | 455 | 1.070 |
Why?
|
| Organ Transplantation | 2 | 2020 | 174 | 1.040 |
Why?
|
| Middle Aged | 58 | 2026 | 27886 | 1.020 |
Why?
|
| Hepatitis B, Chronic | 5 | 2023 | 87 | 1.020 |
Why?
|
| Adult | 58 | 2026 | 30603 | 1.010 |
Why?
|
| Prevalence | 23 | 2026 | 2623 | 0.980 |
Why?
|
| Alcohol Drinking | 3 | 2023 | 338 | 0.890 |
Why?
|
| Elasticity Imaging Techniques | 6 | 2024 | 146 | 0.870 |
Why?
|
| Liver | 11 | 2025 | 1765 | 0.870 |
Why?
|
| Mortality | 4 | 2021 | 254 | 0.830 |
Why?
|
| Male | 69 | 2026 | 62895 | 0.830 |
Why?
|
| Aged | 36 | 2026 | 20512 | 0.820 |
Why?
|
| Transplant Recipients | 3 | 2021 | 230 | 0.810 |
Why?
|
| Hepatitis, Autoimmune | 1 | 2023 | 50 | 0.790 |
Why?
|
| Liver Failure | 3 | 2017 | 89 | 0.770 |
Why?
|
| Female | 68 | 2026 | 68765 | 0.770 |
Why?
|
| Length of Stay | 8 | 2025 | 1378 | 0.760 |
Why?
|
| Cause of Death | 15 | 2025 | 487 | 0.760 |
Why?
|
| Proton Pump Inhibitors | 3 | 2020 | 274 | 0.750 |
Why?
|
| Healthcare Disparities | 3 | 2022 | 492 | 0.720 |
Why?
|
| Drug Overdose | 2 | 2020 | 71 | 0.710 |
Why?
|
| Gastrointestinal Hemorrhage | 2 | 2025 | 225 | 0.710 |
Why?
|
| Liver Cirrhosis, Biliary | 2 | 2020 | 88 | 0.690 |
Why?
|
| Hepatic Encephalopathy | 5 | 2025 | 81 | 0.640 |
Why?
|
| Alcohol-Related Disorders | 1 | 2019 | 34 | 0.620 |
Why?
|
| Gastrointestinal Tract | 1 | 2021 | 218 | 0.610 |
Why?
|
| Gastrectomy | 2 | 2017 | 98 | 0.610 |
Why?
|
| Liver Diseases | 5 | 2023 | 381 | 0.600 |
Why?
|
| Probiotics | 1 | 2021 | 222 | 0.590 |
Why?
|
| Hepatitis C Antibodies | 1 | 2018 | 26 | 0.580 |
Why?
|
| DNA, Viral | 2 | 2018 | 448 | 0.550 |
Why?
|
| Severity of Illness Index | 12 | 2025 | 2999 | 0.550 |
Why?
|
| Diabetes Mellitus | 6 | 2024 | 873 | 0.540 |
Why?
|
| Mesenteric Veins | 1 | 2017 | 14 | 0.530 |
Why?
|
| Shock, Hemorrhagic | 1 | 2017 | 51 | 0.510 |
Why?
|
| Hospital Mortality | 4 | 2020 | 1050 | 0.510 |
Why?
|
| Time Factors | 13 | 2024 | 6172 | 0.510 |
Why?
|
| Portal Vein | 1 | 2017 | 88 | 0.510 |
Why?
|
| Skilled Nursing Facilities | 1 | 2016 | 7 | 0.500 |
Why?
|
| Transplants | 1 | 2016 | 36 | 0.490 |
Why?
|
| Secondary Prevention | 1 | 2017 | 219 | 0.480 |
Why?
|
| Postoperative Complications | 3 | 2025 | 3076 | 0.480 |
Why?
|
| Proportional Hazards Models | 9 | 2025 | 1370 | 0.480 |
Why?
|
| Cardiovascular Diseases | 7 | 2025 | 2038 | 0.470 |
Why?
|
| Venous Thrombosis | 1 | 2017 | 168 | 0.460 |
Why?
|
| Health Care Costs | 4 | 2024 | 393 | 0.450 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2019 | 283 | 0.450 |
Why?
|
| Hospital Costs | 1 | 2016 | 177 | 0.440 |
Why?
|
| Databases, Factual | 8 | 2022 | 1198 | 0.430 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2021 | 796 | 0.410 |
Why?
|
| Treatment Outcome | 18 | 2025 | 12583 | 0.410 |
Why?
|
| Colonic Neoplasms | 1 | 2016 | 257 | 0.400 |
Why?
|
| Acute-On-Chronic Liver Failure | 2 | 2025 | 71 | 0.390 |
Why?
|
| Risk Assessment | 13 | 2024 | 3596 | 0.390 |
Why?
|
| Hepatitis, Viral, Human | 2 | 2023 | 42 | 0.390 |
Why?
|
| Biliary Tract Neoplasms | 2 | 2024 | 20 | 0.380 |
Why?
|
| Cholangitis, Sclerosing | 2 | 2025 | 74 | 0.380 |
Why?
|
| Cholangiocarcinoma | 3 | 2024 | 124 | 0.380 |
Why?
|
| Young Adult | 13 | 2025 | 9702 | 0.370 |
Why?
|
| Patient Readmission | 3 | 2020 | 413 | 0.360 |
Why?
|
| Cohort Studies | 8 | 2025 | 4987 | 0.360 |
Why?
|
| Incidence | 8 | 2026 | 3261 | 0.360 |
Why?
|
| Laparoscopy | 1 | 2017 | 518 | 0.360 |
Why?
|
| Cross-Sectional Studies | 11 | 2025 | 3710 | 0.350 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2019 | 1055 | 0.350 |
Why?
|
| Ascites | 4 | 2025 | 98 | 0.350 |
Why?
|
| Aged, 80 and over | 10 | 2024 | 6716 | 0.350 |
Why?
|
| Health Policy | 2 | 2025 | 223 | 0.330 |
Why?
|
| Registries | 4 | 2019 | 1540 | 0.290 |
Why?
|
| Hypothyroidism | 2 | 2020 | 78 | 0.290 |
Why?
|
| Disease Progression | 7 | 2025 | 2125 | 0.290 |
Why?
|
| Inpatients | 4 | 2020 | 540 | 0.280 |
Why?
|
| Health Status Disparities | 3 | 2020 | 269 | 0.270 |
Why?
|
| Opioid-Related Disorders | 2 | 2021 | 287 | 0.260 |
Why?
|
| Recurrence | 3 | 2021 | 1422 | 0.260 |
Why?
|
| Esophageal and Gastric Varices | 2 | 2025 | 72 | 0.260 |
Why?
|
| Kidney Transplantation | 2 | 2025 | 560 | 0.260 |
Why?
|
| Cost of Illness | 3 | 2026 | 284 | 0.230 |
Why?
|
| Metabolic Diseases | 2 | 2024 | 132 | 0.230 |
Why?
|
| Preoperative Period | 3 | 2020 | 88 | 0.230 |
Why?
|
| Cholangitis | 1 | 2025 | 40 | 0.220 |
Why?
|
| Troponin | 1 | 2025 | 70 | 0.220 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2025 | 735 | 0.220 |
Why?
|
| Intention to Treat Analysis | 1 | 2024 | 61 | 0.220 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2026 | 134 | 0.220 |
Why?
|
| Depression | 3 | 2023 | 1296 | 0.210 |
Why?
|
| Pulse Wave Analysis | 1 | 2024 | 50 | 0.210 |
Why?
|
| Donor Selection | 1 | 2024 | 58 | 0.210 |
Why?
|
| Hepatitis A | 1 | 2024 | 28 | 0.210 |
Why?
|
| Organ Preservation | 1 | 2025 | 62 | 0.210 |
Why?
|
| HIV | 1 | 2025 | 171 | 0.210 |
Why?
|
| Republic of Korea | 1 | 2024 | 52 | 0.210 |
Why?
|
| Telemedicine | 2 | 2023 | 490 | 0.210 |
Why?
|
| Perfusion | 1 | 2025 | 207 | 0.210 |
Why?
|
| Age Distribution | 3 | 2019 | 423 | 0.200 |
Why?
|
| Vascular Stiffness | 1 | 2024 | 78 | 0.200 |
Why?
|
| Opiate Substitution Treatment | 2 | 2021 | 38 | 0.200 |
Why?
|
| Adolescent | 6 | 2024 | 20156 | 0.200 |
Why?
|
| Policy | 1 | 2023 | 34 | 0.200 |
Why?
|
| Adenocarcinoma | 2 | 2023 | 972 | 0.190 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2025 | 327 | 0.190 |
Why?
|
| California | 2 | 2020 | 124 | 0.190 |
Why?
|
| Glucocorticoids | 1 | 2025 | 337 | 0.190 |
Why?
|
| Chi-Square Distribution | 3 | 2018 | 561 | 0.180 |
Why?
|
| Bile Duct Neoplasms | 1 | 2023 | 125 | 0.180 |
Why?
|
| Interrupted Time Series Analysis | 1 | 2021 | 25 | 0.180 |
Why?
|
| Hepatitis B | 1 | 2023 | 166 | 0.180 |
Why?
|
| Viremia | 1 | 2022 | 129 | 0.180 |
Why?
|
| Prebiotics | 1 | 2021 | 26 | 0.180 |
Why?
|
| Alcohol Abstinence | 1 | 2021 | 15 | 0.180 |
Why?
|
| Health Care Rationing | 1 | 2021 | 59 | 0.170 |
Why?
|
| Gallbladder Neoplasms | 1 | 2021 | 14 | 0.170 |
Why?
|
| Cholestasis | 1 | 2023 | 166 | 0.170 |
Why?
|
| Military Personnel | 1 | 2023 | 208 | 0.170 |
Why?
|
| Tacrolimus | 1 | 2021 | 100 | 0.170 |
Why?
|
| Hypernatremia | 1 | 2021 | 32 | 0.170 |
Why?
|
| Age Factors | 4 | 2024 | 2814 | 0.170 |
Why?
|
| Acute Kidney Injury | 2 | 2025 | 664 | 0.170 |
Why?
|
| Hyponatremia | 1 | 2021 | 74 | 0.170 |
Why?
|
| Healthy Lifestyle | 1 | 2020 | 32 | 0.170 |
Why?
|
| Hepatitis B virus | 2 | 2023 | 137 | 0.170 |
Why?
|
| Vaccines, Synthetic | 1 | 2021 | 316 | 0.160 |
Why?
|
| Exercise | 3 | 2021 | 845 | 0.160 |
Why?
|
| Dysbiosis | 1 | 2021 | 138 | 0.160 |
Why?
|
| Peritonitis | 2 | 2017 | 74 | 0.160 |
Why?
|
| Sarcopenia | 1 | 2021 | 55 | 0.160 |
Why?
|
| Prediabetic State | 1 | 2021 | 65 | 0.160 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 2020 | 74 | 0.160 |
Why?
|
| Digestive System Diseases | 1 | 2020 | 20 | 0.160 |
Why?
|
| Multivariate Analysis | 3 | 2019 | 1388 | 0.160 |
Why?
|
| Biliary Atresia | 1 | 2023 | 217 | 0.160 |
Why?
|
| Thyroid Gland | 1 | 2020 | 99 | 0.160 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2023 | 1239 | 0.160 |
Why?
|
| Causality | 1 | 2019 | 88 | 0.160 |
Why?
|
| Follow-Up Studies | 4 | 2025 | 5161 | 0.150 |
Why?
|
| Methadone | 1 | 2020 | 126 | 0.150 |
Why?
|
| Fibrosis | 4 | 2024 | 400 | 0.150 |
Why?
|
| Entamoebiasis | 1 | 2019 | 3 | 0.150 |
Why?
|
| Entamoeba histolytica | 1 | 2019 | 14 | 0.150 |
Why?
|
| Marijuana Smoking | 1 | 2019 | 31 | 0.150 |
Why?
|
| Drug Monitoring | 1 | 2021 | 275 | 0.150 |
Why?
|
| Phenols | 1 | 2019 | 66 | 0.150 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2020 | 228 | 0.150 |
Why?
|
| Analgesics, Opioid | 2 | 2021 | 457 | 0.140 |
Why?
|
| Colonic Diseases | 1 | 2019 | 37 | 0.140 |
Why?
|
| Benzhydryl Compounds | 1 | 2019 | 74 | 0.140 |
Why?
|
| Marijuana Abuse | 1 | 2019 | 53 | 0.140 |
Why?
|
| Metabolic Syndrome | 1 | 2021 | 345 | 0.140 |
Why?
|
| Sex Distribution | 1 | 2019 | 316 | 0.140 |
Why?
|
| Global Burden of Disease | 1 | 2017 | 27 | 0.140 |
Why?
|
| Rifamycins | 1 | 2017 | 18 | 0.140 |
Why?
|
| Bacterial Infections | 2 | 2017 | 322 | 0.130 |
Why?
|
| Licensed Practical Nurses | 1 | 2017 | 1 | 0.130 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2021 | 320 | 0.130 |
Why?
|
| Immunosuppressive Agents | 1 | 2021 | 652 | 0.130 |
Why?
|
| Sofosbuvir | 1 | 2017 | 20 | 0.130 |
Why?
|
| Hepatorenal Syndrome | 1 | 2017 | 29 | 0.130 |
Why?
|
| Heterocyclic Compounds, 4 or More Rings | 1 | 2017 | 34 | 0.130 |
Why?
|
| Carbamates | 1 | 2017 | 55 | 0.130 |
Why?
|
| Thrombophilia | 1 | 2017 | 39 | 0.130 |
Why?
|
| Nutritional Support | 1 | 2017 | 67 | 0.130 |
Why?
|
| Time-to-Treatment | 1 | 2018 | 200 | 0.130 |
Why?
|
| Pancreatic Neoplasms | 1 | 2023 | 713 | 0.130 |
Why?
|
| United States Health Resources and Services Administration | 1 | 2016 | 2 | 0.130 |
Why?
|
| Clostridium Infections | 1 | 2020 | 242 | 0.130 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2018 | 275 | 0.120 |
Why?
|
| Medically Underserved Area | 1 | 2017 | 87 | 0.120 |
Why?
|
| Case-Control Studies | 2 | 2023 | 3332 | 0.120 |
Why?
|
| RNA, Messenger | 1 | 2021 | 2542 | 0.120 |
Why?
|
| Heparin | 1 | 2017 | 206 | 0.120 |
Why?
|
| Income | 1 | 2016 | 132 | 0.120 |
Why?
|
| Computed Tomography Angiography | 1 | 2017 | 209 | 0.120 |
Why?
|
| Nutritional Status | 1 | 2017 | 299 | 0.120 |
Why?
|
| Antibodies, Viral | 1 | 2021 | 1133 | 0.120 |
Why?
|
| Malnutrition | 1 | 2017 | 148 | 0.120 |
Why?
|
| Survival Analysis | 4 | 2022 | 1500 | 0.110 |
Why?
|
| Educational Status | 1 | 2016 | 276 | 0.110 |
Why?
|
| HIV Infections | 2 | 2025 | 1954 | 0.110 |
Why?
|
| Insurance, Health | 1 | 2016 | 135 | 0.110 |
Why?
|
| Lymph Node Excision | 1 | 2016 | 167 | 0.110 |
Why?
|
| Decision Support Techniques | 1 | 2018 | 291 | 0.110 |
Why?
|
| Heterozygote | 1 | 2017 | 691 | 0.110 |
Why?
|
| Health Resources | 1 | 2016 | 127 | 0.110 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2020 | 756 | 0.110 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2016 | 251 | 0.110 |
Why?
|
| Survival Rate | 4 | 2020 | 2110 | 0.110 |
Why?
|
| Lymph Nodes | 1 | 2016 | 374 | 0.100 |
Why?
|
| Health Services Accessibility | 2 | 2017 | 662 | 0.100 |
Why?
|
| Logistic Models | 3 | 2025 | 1791 | 0.100 |
Why?
|
| Allografts | 2 | 2025 | 189 | 0.100 |
Why?
|
| Anticoagulants | 1 | 2017 | 581 | 0.090 |
Why?
|
| Kidney | 1 | 2019 | 1283 | 0.090 |
Why?
|
| Veterans | 1 | 2023 | 1744 | 0.090 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2016 | 484 | 0.090 |
Why?
|
| Decision Making | 1 | 2016 | 666 | 0.090 |
Why?
|
| Prospective Studies | 4 | 2023 | 6247 | 0.090 |
Why?
|
| Comorbidity | 3 | 2023 | 1563 | 0.090 |
Why?
|
| Kidney Failure, Chronic | 1 | 2019 | 924 | 0.090 |
Why?
|
| Morbidity | 2 | 2023 | 252 | 0.080 |
Why?
|
| Prognosis | 4 | 2023 | 4803 | 0.080 |
Why?
|
| Medicaid | 2 | 2023 | 242 | 0.080 |
Why?
|
| Hepatitis B Surface Antigens | 2 | 2023 | 53 | 0.080 |
Why?
|
| ROC Curve | 2 | 2023 | 592 | 0.080 |
Why?
|
| Observational Studies as Topic | 2 | 2023 | 97 | 0.080 |
Why?
|
| Stomach Neoplasms | 1 | 2016 | 565 | 0.080 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2025 | 1206 | 0.080 |
Why?
|
| Chronic Disease | 3 | 2018 | 1200 | 0.080 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2017 | 2048 | 0.080 |
Why?
|
| Censuses | 2 | 2019 | 11 | 0.080 |
Why?
|
| Child | 3 | 2024 | 25302 | 0.070 |
Why?
|
| Sex Factors | 2 | 2024 | 1314 | 0.070 |
Why?
|
| Biopsy | 2 | 2023 | 1237 | 0.070 |
Why?
|
| Linear Models | 2 | 2020 | 686 | 0.070 |
Why?
|
| SEER Program | 2 | 2021 | 201 | 0.070 |
Why?
|
| Quality of Life | 1 | 2017 | 2032 | 0.070 |
Why?
|
| Ultrasonography | 2 | 2024 | 941 | 0.070 |
Why?
|
| Body Mass Index | 2 | 2024 | 1659 | 0.070 |
Why?
|
| Odds Ratio | 2 | 2021 | 1218 | 0.060 |
Why?
|
| Anti-Bacterial Agents | 1 | 2017 | 2519 | 0.060 |
Why?
|
| Renal Dialysis | 2 | 2025 | 936 | 0.060 |
Why?
|
| North America | 1 | 2025 | 250 | 0.060 |
Why?
|
| Prednisolone | 1 | 2025 | 65 | 0.060 |
Why?
|
| Cost-Benefit Analysis | 2 | 2018 | 535 | 0.060 |
Why?
|
| Primary Graft Dysfunction | 1 | 2025 | 31 | 0.050 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 1 | 2024 | 31 | 0.050 |
Why?
|
| Neoplasms | 1 | 2019 | 2852 | 0.050 |
Why?
|
| Agent Orange | 1 | 2023 | 3 | 0.050 |
Why?
|
| Drug Therapy, Combination | 2 | 2018 | 1148 | 0.050 |
Why?
|
| Reperfusion Injury | 1 | 2025 | 108 | 0.050 |
Why?
|
| Electronic Health Records | 2 | 2023 | 781 | 0.050 |
Why?
|
| Mutation | 1 | 2017 | 5950 | 0.050 |
Why?
|
| Predictive Value of Tests | 2 | 2020 | 2240 | 0.050 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2023 | 89 | 0.050 |
Why?
|
| Food Supply | 1 | 2024 | 90 | 0.050 |
Why?
|
| Hand Strength | 1 | 2022 | 56 | 0.050 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2023 | 104 | 0.050 |
Why?
|
| Living Donors | 1 | 2023 | 115 | 0.050 |
Why?
|
| Ethanol | 1 | 2023 | 159 | 0.050 |
Why?
|
| Muscle Strength | 1 | 2022 | 79 | 0.050 |
Why?
|
| Acute Disease | 1 | 2025 | 1142 | 0.050 |
Why?
|
| Ontario | 1 | 2021 | 84 | 0.040 |
Why?
|
| Estradiol | 1 | 2023 | 477 | 0.040 |
Why?
|
| Early Diagnosis | 1 | 2022 | 188 | 0.040 |
Why?
|
| alpha-Fetoproteins | 1 | 2022 | 134 | 0.040 |
Why?
|
| Graft Rejection | 1 | 2025 | 559 | 0.040 |
Why?
|
| Hypoglycemic Agents | 1 | 2024 | 456 | 0.040 |
Why?
|
| Insurance Coverage | 1 | 2021 | 116 | 0.040 |
Why?
|
| Respiratory Protective Devices | 1 | 2020 | 8 | 0.040 |
Why?
|
| Animals | 1 | 2021 | 33212 | 0.040 |
Why?
|
| Sodium | 1 | 2021 | 275 | 0.040 |
Why?
|
| Obesity | 2 | 2024 | 2338 | 0.040 |
Why?
|
| Aspartate Aminotransferases | 1 | 2020 | 80 | 0.040 |
Why?
|
| Platelet Count | 1 | 2020 | 132 | 0.040 |
Why?
|
| Death Certificates | 1 | 2019 | 11 | 0.040 |
Why?
|
| Alanine Transaminase | 1 | 2020 | 154 | 0.040 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2023 | 694 | 0.040 |
Why?
|
| Paromomycin | 1 | 2019 | 4 | 0.040 |
Why?
|
| Protective Factors | 1 | 2019 | 90 | 0.040 |
Why?
|
| Weight Loss | 1 | 2023 | 503 | 0.040 |
Why?
|
| Thyrotropin | 1 | 2018 | 53 | 0.040 |
Why?
|
| Datasets as Topic | 1 | 2019 | 102 | 0.040 |
Why?
|
| Antiprotozoal Agents | 1 | 2019 | 40 | 0.040 |
Why?
|
| Risk | 1 | 2020 | 735 | 0.040 |
Why?
|
| Early Detection of Cancer | 1 | 2022 | 396 | 0.040 |
Why?
|
| Testosterone | 1 | 2023 | 597 | 0.030 |
Why?
|
| Sustained Virologic Response | 1 | 2018 | 46 | 0.030 |
Why?
|
| Myositis | 1 | 2019 | 100 | 0.030 |
Why?
|
| Patient Compliance | 1 | 2020 | 464 | 0.030 |
Why?
|
| Hepatitis B e Antigens | 1 | 2016 | 14 | 0.030 |
Why?
|
| Patient Portals | 1 | 2017 | 20 | 0.030 |
Why?
|
| Coinfection | 1 | 2019 | 185 | 0.030 |
Why?
|
| Computer Security | 1 | 2017 | 27 | 0.030 |
Why?
|
| Ambulatory Care | 1 | 2020 | 398 | 0.030 |
Why?
|
| Markov Chains | 1 | 2017 | 95 | 0.030 |
Why?
|
| Nutrition Assessment | 1 | 2017 | 124 | 0.030 |
Why?
|
| Advanced Practice Nursing | 1 | 2016 | 8 | 0.030 |
Why?
|
| Colonoscopy | 1 | 2019 | 244 | 0.030 |
Why?
|
| Polyethylene Glycols | 1 | 2018 | 240 | 0.030 |
Why?
|
| Confidentiality | 1 | 2017 | 104 | 0.030 |
Why?
|
| Immunization, Passive | 1 | 2016 | 120 | 0.030 |
Why?
|
| Safety-net Providers | 1 | 2017 | 84 | 0.030 |
Why?
|
| Interferon-alpha | 1 | 2018 | 237 | 0.030 |
Why?
|
| Drug Combinations | 1 | 2017 | 271 | 0.030 |
Why?
|
| Glomerular Filtration Rate | 1 | 2019 | 539 | 0.030 |
Why?
|
| Postoperative Care | 1 | 2018 | 307 | 0.030 |
Why?
|
| Biomarkers | 1 | 2025 | 3252 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2018 | 304 | 0.030 |
Why?
|
| Preoperative Care | 1 | 2018 | 355 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2019 | 561 | 0.030 |
Why?
|
| Palliative Care | 1 | 2019 | 437 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2019 | 1436 | 0.030 |
Why?
|
| Health Personnel | 1 | 2020 | 535 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2017 | 686 | 0.030 |
Why?
|
| Muscle, Skeletal | 1 | 2021 | 973 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2016 | 425 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 2018 | 1295 | 0.030 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2024 | 1357 | 0.030 |
Why?
|
| Patient Selection | 1 | 2018 | 713 | 0.030 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2019 | 482 | 0.030 |
Why?
|
| Biomarkers, Tumor | 1 | 2022 | 1562 | 0.030 |
Why?
|
| Anxiety | 1 | 2020 | 964 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 1277 | 0.030 |
Why?
|
| Algorithms | 1 | 2020 | 1638 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2019 | 1868 | 0.020 |
Why?
|
| Cesarean Section | 1 | 2016 | 425 | 0.020 |
Why?
|
| Diet | 1 | 2020 | 1105 | 0.020 |
Why?
|
| Communication | 1 | 2017 | 513 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2020 | 8372 | 0.020 |
Why?
|
| Infant | 1 | 2020 | 12811 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2020 | 14467 | 0.010 |
Why?
|
| Pregnancy | 1 | 2016 | 7426 | 0.010 |
Why?
|